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Thecoet-effectivenessof preventinginitial
coronaryeventswithpravaatatin:Resultsof the
WestofScotlandCoronaryPreventionStudy
economicanalysis
West of Scotland Coronary Prevention Study Economic Analysia Group,
J. Shepherd. University Department of Pathological Biocfremist~, Glasgow
Royal Infimray, GlasgowG40S5 USA
Purpose: To examinethe economic implications of treating hypercholes-
terulemic middle aged men (4.5-64 yrs) with pravastatin (40 m~day) in order
to prevent cardiovascular diaease.
Methods: A cost-conasquence analysis was performed from the UK Na-
tional Health Setvice perspective utilising clinical event information from the
Weat of Scotland Coronaty Prevention Study (WOSCOPS), UK cost data
and peat clinical event life expectancy information derived from the Scottish
Record Linkage databaae. Hazard rates for experiencing an initial cardio-
vascular event (Ml, CHD death, PTCA, etc) were calculated for placebo
and pravaatatin. These were combined with the coat of treatihg the initial
events, the life expectancy associated with them, and compliance-adjusted
drug dispensing In a cohort model. Incremental cost-effectiveness ratios
were calculated. Sensitivity analysea were conducted for the discount rate,
initial hazard rates, type of initial events considered, and other modellin9
aaaumptions.
Resu/te: Over 5 yeare, treatment with pravastatin of 10,000 men like
thoae in WOSCOPS would prevent about 300 of them from developing
cardiovascular diseaae, de~”nding on its definition. The incremental coet-
effectiveness ratios associated with the prevention of these eventa range
from fl0,000 to 220,000 per life year saved. The ratio decreaaed further in
higher rick men, (eg those who smoke, have hypertension, and are older).
Conclusions: Regardleea of modelling assumptions, pravastatin therapy
in hypercholeeterolemic men for the primary prevention of cardiovascular
disease is comparable economically in the UK to other currently funded
health-care intervention.
D96855 HospitalOutcomesinHeartFailureareSuperiorat
a LargeTettiaryCareTeachingInstitution
E.F. Philbin, T.G. DiSalvo. Maaeachuseffs General Hospital & Harvard
Medical School, Boston, MA, USA
To batter understand the differences in congestive heafl failure (CHF) out-
comes between tertiary care centers and community hospitals, we examined
length of atay (LOS) and mortality rate among consecutive DRG 127 patients
admitted to one large tertiary care university hospital and 10 amaller oom-
munity hospitals. Information was obtained from the hoapitals’ administrative
datebases and confirmed by chart review. Only the first hospital admisaion
for each patient during the study period was included in the analyaes. 1,127
eligible patients were admitted to the university center between October 1992
and April 1996, while 1,328 such patients were identified at the community
hospitala during 1995. The crude outcomes of these subjects are shown in
the Table:
Outcome University Community P
Lengthof stay,days+ SD 6.4+ 6.4 8.0* 9.4 0.000001
Mortalityrate,% 2.8 6.0 0.0003
After adjusting for demographic differences, the mortality rate was lower
for the university group (odds ratio= 0.51, Cl =0.33-0.78, p= 0.002). Similar
findings were obsetved when interhospital transfers and eleotiveadmiesions,
representing only 11%of the study cohort, were excluded from the analyses
(odda ratio =0.45, Cl = 0.27-0.73, p= 0.002). Moreover, similar results were
obtained when only thoee subjecte whose discharge occurred during 1995
were included (odda ratio= 0.55, Cl= 0.30-1.03, p= 0.06). Ineimilarfashion,
adjusted LOS wee significantly shorter for the university group when these
aubenalyses were performed. We oonclude that adjusted mortality rate and
LOS are both lower among patients treated for CHF at a single tertiary care
university hospital than smaller community hospitala. Further investigation is
naceasary to determine whether these findings reflect differences in patient
characteristic or process of care.
l-l TreatmentOfHeartFaik!reinthe National
AmbulatoryMedicalCareSurvey(NAMCS)
K.D. Aaronson, S.A. Glied, J.E. Siak. College of Physicians and Surgeons
and School of Public Health, Columbia University New York, NY USA
Clinical trials have proven the efficacy of ACE Inhibitom (ACEI) and hy-
dralazine with nitrates (H/N) for the treatment of chronic heari failure. We
sought to investigate the extent to which drug therapy for CHF in the oom-
munity setting reflecta the results of these studies.
NAMCS is an annual, nationally representative survey of outpatient care
delivered by physicians. Diagnoses and medications are recorded for each
surveyed vieit. Since most of the relevant trials were published by 1991,
we examined data from the three most recently available NAMCS (1990
through 1992). CHF was identified by DRG 127 or ICD-9 426. We performed
multivariable logistic regression to examine simultaneously the impact of
provider specialty; patientage, sex and race; and study year on phyaician
prescribing behavior. The proportion of patients receiving ACEI for each
survey year is shown:
1990 1991 1992
Overall(unweighed) 22% 27% 34”/0
FPIGP 180/. 13”A 15”/0
Internists 20% 16°4
Cardiologists
35%
31% 58”/o 40”A
FP isfamily physicianaand GP is general preotitionere. Logiatic regression
confirmed that cardiologists were more likely to prescribe ACEI (P <0.001
vs. each other group) and showed no increaae in ACEI uae over time (the
increased overall ACEI use was due to relative oversampling of Cardiologi$ta
in later years). There was no difference in ACEI use by patient age, sex or
race. H/N was uaed by < 1%, IYo and O%of patients not receiving an ACEI.
Although cardiologists were more likely to preacribe ACEI than other
physicians, ACEI use remained infrequent, and did not increase over time.
True drug contraindications are unlikely to fully account for these findings.
Differences in disease aeverity (not aasesaed in NAMCS) could acmunt for
the differences seen between specialties.
D96857 NursePractitionerManagedAnginaClinicImprovesQualityof Life
C.M. Dougherty,J. Spertus, W.P. Nichol, T. Dewhurst. Puget Sound VA
Medical Centerarrd The Polyclinic, Seattle, WA, USA
The purpoaeof this study was to determine the effects of a nurse practitioner
managed angina clinic (AC) on quality of life, angina symptoma, and func-
tional status when compared to a general internal medicine clinic (GIMC) in
persons with chronic stable angina. Methods: 107 men from the GIMC were
allocated to receive cardiac care in the AC, where care was implemented by
a nurse practitioner with cardiology consultation, or to receive standard esre
(N =847) in the GIMC by staff or resident MDsand ARNPs. Angina treatment
waa optimized for AC patients using a standardized protbcol and patients
were followed for 6 months. GIMC patients were sent questionnaires every
three months and followed as deemed necesaaty by their primary providers.
The primary outcomes were and quality of life scores as measured by the
Seattle Angina Questionnaire (SAQ) and Shorf Form Health Survey (SF-36).
Resu/ts: No differences were noted between baseline demographic, med-
ication, or primary outcomes in the 107 AC or the 647 GIMC patients. At
3 months, the AC patients demonstrated highly significant improvement in
angina frequency,angina stability, treatment satisfaction, quality of life, eoeial
functioning & mental health scores over the GIMC group. At 6 months, theae
treatment effects were suatained at the same level, with no further improve-
ments noted in either group. Neither group experienced improvement in
physical limitations or exertional capacity. Conclusion: The use of a nurse
practitioner managed angina clinic resulted in significant improvements in
angina control, quality of life, and treatment satisfaction above that provided
by standard care available in an internal medicine clinic. Specialized nurse
practitioners can safely and effectively manage chronic stable angina at a
higher level than that of a general madicine clinic.
